Surveillance for azole resistance in clinical and environmental isolates of Aspergillus fumigatus in Australia and cyp51A homology modelling of azole-resistant isolates

The Journal of Antimicrobial Chemotherapy
Jessica J TalbotSharon C-A Chen

Abstract

The prevalence of azole resistance in Aspergillus fumigatus is uncertain in Australia. Azole exposure may select for resistance. We investigated the frequency of azole resistance in a large number of clinical and environmental isolates. A. fumigatus isolates [148 human, 21 animal and 185 environmental strains from air (n = 6) and azole-exposed (n = 64) or azole-naive (n = 115) environments] were screened for azole resistance using the VIPcheck™ system. MICs were determined using the Sensititre™ YeastOne YO10 assay. Sequencing of the Aspergillus cyp51A gene and promoter region was performed for azole-resistant isolates, and cyp51A homology protein modelling undertaken. Non-WT MICs/MICs at the epidemiological cut-off value of one or more azoles were observed for 3/148 (2%) human isolates but not amongst animal, or environmental, isolates. All three isolates grew on at least one azole-supplemented well based on VIPcheck™ screening. For isolates 9 and 32, the itraconazole and posaconazole MICs were 1 mg/L (voriconazole MICs 0.12 mg/L); isolate 129 had itraconazole, posaconazole and voriconazole MICs of >16, 1 and 8 mg/L, respectively. Soil isolates from azole-exposed and azole-naive environments had similar geometric mean MICs of i...Continue Reading

References

Apr 1, 1995·Applied and Environmental Microbiology·N L Glass, G C Donaldson
Mar 30, 2004·Proteins·Matthew P JacobsonRichard A Friesner
May 9, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Ben De PauwUNKNOWN National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group
Apr 21, 2009·Applied and Environmental Microbiology·Eveline SneldersPaul E Verweij
Nov 21, 2009·The Lancet Infectious Diseases·Paul E VerweijWillem J G Melchers
Feb 9, 2011·Antimicrobial Agents and Chemotherapy·M G FraczekP Bowyer
Oct 18, 2011·Emerging Infectious Diseases·Jan W M van der LindenPaul E Verweij
Dec 21, 2012·Science Translational Medicine·Gordon D BrownTheodore C White
Jan 30, 2015·The Journal of Antimicrobial Chemotherapy·J SteinmannP-M Rath
Apr 18, 2015·Mycoses·Sarah E KiddPaul E Verweij
May 20, 2015·Emerging Infectious Diseases·J W M van der LindenP E Verweij
Jul 2, 2016·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Thomas F PattersonJohn E Bennett
Aug 3, 2016·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Thomas F PattersonJohn E Bennett
Feb 27, 2017·Drugs·Rocio Garcia-RubioEmilia Mellado
Aug 5, 2017·The Lancet Infectious Diseases·David S PerlinAna Alastruey-Izquierdo
Sep 16, 2017·The Journal of Infectious Diseases·Anuradha ChowdharyJacques F Meis

❮ Previous
Next ❯

Citations

Jul 25, 2019·Journal of Fungi·Daniel Z P Friedman, Ilan S Schwartz
Jan 29, 2020·American Journal of Respiratory Cell and Molecular Biology·Shuang LiuJu Cao
Jan 30, 2020·Frontiers in Microbiology·Sarah E KiddCatriona L Halliday
Feb 2, 2021·Pathology·Arthur J MorrisSally A Roberts
Dec 24, 2018·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·P P A LestradeP E Verweij
May 27, 2021·Studies in Mycology·A ArastehfarM Hoenigl
Dec 24, 2020·Applied and Environmental Microbiology·Rocio Garcia-RubioEmilia Mellado
Jul 29, 2021·Medical Mycology·Aryse Martins MeloMelissa Orzechowski Xavier
Dec 23, 2021·Internal Medicine Journal·Abby P DouglasUNKNOWN Australasian Antifungal Guidelines Steering Committee
Dec 23, 2021·Internal Medicine Journal·Benjamin W TehUNKNOWN Australasian Antifungal Guidelines Steering Committee
Dec 7, 2021·Microbiology and Immunology·Sofia Marisel Rivelli Zea, Takahito Toyotome

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Aspergillosis

Aspergillosis is the name given to a wide variety of diseases caused by infection by fungi of the genus Aspergillus. Aspergillosis occurs in chronic or acute forms which are clinically very distinct. Most cases of acute aspergillosis occur in patients with severely compromised immune systems. Chronic colonization or infection can cause complications in people with underlying respiratory illnesses. Discover the latest research on aspergillosis here.

Aspergillosis (ASM)

Aspergillosis is the name given to a wide variety of diseases caused by infection by fungi of the genus Aspergillus. Aspergillosis occurs in chronic or acute forms which are clinically very distinct. Most cases of acute aspergillosis occur in patients with severely compromised immune systems. Chronic colonization or infection can cause complications in people with underlying respiratory illnesses. Discover the latest research on aspergillosis here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

© 2022 Meta ULC. All rights reserved